Quintiles said it acquired Expression Analysis (EA), a provider of genomics testing and analysis, for an undisclosed price with greater personalized medicine development in mind.
The deal combines Quintiles’ network of more than 25,000 professionals in 60 countries—as well as its clinical, commercial, consulting and capital biopharmaceutical services—with EA’s offerings, which include whole genome to focused-set gene expression profiling and genotyping assays; DNA and RNA sequencing services; sequence enrichment technologies; and bioinformatics support.
“The addition of EA’s Genomic Know-How® to Quintiles is another step forward in our efforts to bring personalized medicine into mainstream drug development,” Thomas Wollman, svp, Quintiles Global Laboratories, said in a statement.
Said Steve McPhail, EA President and CEO, in the same statement: “Our mission perfectly fits Quintiles’ strategy to use genomic data and advanced informatics to yield actionable insights and more effective personalized treatments.”
Quintiles Global Laboratories supports trials worldwide with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore, and Japan, and a network of affiliate labs in Argentina and Brazil.
